Up 35% on Buyout: InterMune inc Investor Key Takeaways | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 25 August, 2014 by The TZ Newswire Staff

Up 35% on Buyout: InterMune inc Investor Key Takeaways

FDA’s rejection of InterMune’s Esbriet hurt investors, but Roche clearly thinks the drug will be approved.

See also
- Next Article The Online Travel Industry: Investing Essentials
- Previous Article Why ‘S&P 2000’ Is A Fed-Manufactured Mirage: The “Buy The Dips” Chart That Says It All
Editorial Calender

August 2014

M T W T F S S

1 2 3

4 5 6 7 8 9 10

11 12 13 14 15 16 17

18 19 20 21 22 23 24

25 26 27 28 29 30 31

« Jul Sep »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar